Clinical Trial Update: Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the effects of phosphorylcholine PC-mAb in subjects with elevated lipoprotein(a) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• Phosphorylcholine PC-mAb (phosphorylcholine monoclonal antibody)

Snippet

Sponsor: Athera Biotechnologies AB | Conditions: Arterial Inflammation, Cardiovascular Diseases | Phase 2 | Status: TERMINATED